Amy L Jonson
Affiliation: University of Minnesota
- Gonadal dysgenesis and gynecologic cancerAmy L Jonson
Division of Gynecologic Oncology, University of Minnesota Department of Obstetrics, Gynecology, Women s Health, Minneapolis, Minnesota, USA
Obstet Gynecol 116:550-2. 2010..Gonadal dysgenesis encompasses a variety of sexual differentiation disorders. Within this population of patients, there is an increased risk of gonadal tumor formation...
- Learning about ovarian cancer at the time of diagnosis: video versus usual careMelissa A Geller
Obstetrics and Gynecology, University of Minnesota, Minneapolis, MN, USA
Gynecol Oncol 119:370-5. 2010..We evaluated the effects of an educational video on patients' distress, cancer knowledge, coping skills and attitudes regarding learning about cancer at the time of ovarian cancer diagnosis...
- A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a "Sandwich" method for stage III, IV, and recurrent endometrial cancerMelissa A Geller
Department of Obstetrics, Gynecology and Women s Health, Division of Gynecologic Oncology, University of Minnesota, Minneapolis, MN, USA
Gynecol Oncol 121:112-7. 2011..To determine feasibility and efficacy of administering docetaxel and carboplatin chemotherapy followed by pelvic radiotherapy and then consolidation chemotherapy in patients with advanced or recurrent endometrial cancer...
- A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancerMelissa A Geller
Obstetrics and Gynecology, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN 55455, USA
Cytotherapy 13:98-107. 2011..We evaluated the tumor response and in vivo expansion of allogeneic NK cells in recurrent ovarian and breast cancer...
- Gene silencing with siRNA targeting E6/E7 as a therapeutic intervention in a mouse model of cervical cancerAmy L Jonson
University of Minnesota Medical School, Department of Obstetrics, Gynecology and Women s Health, 420 Delaware Street S E, MMC 395, Minneapolis, MN 55455 0374, USA
Gynecol Oncol 111:356-64. 2008..Our objective was to determine if siRNA targeting E6/E7 would inhibit the growth of established tumors in a mouse model of cervical cancer...
- A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancerPeter A Argenta
Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Women s Health, University of Minnesota, Minneapolis MN 55455, USA
Gynecol Oncol 113:205-9. 2009..Grade 1 toxicity included headache (1 patient) and bromidrosis (2 patients). Conclusions. Fulvestrant is well-tolerated and efficacious. Objective response rates are low, but disease stabilization was common...